Elsevier,
The Lancet Global Health, Volume 11, June 2023
This Comment supports SDGs 4 and 10 by reviewing the global pledges and resolutions that have been made regarding disabled children (dating back to 1946), and highlighting how the September 2023 global summit on SDGs provides an opportunity to reaffirm global commitments on early childhood development.
Elsevier,
The Lancet Rheumatology, Volume 5, June 2023
This Article supports SDG 3 by estimating the burden of low back pain, which continues to be the leading cause of disability worldwide. The study predicts that low back pain prevalence will continue to increase, from 619 million people in 2020 to 843 million in 2050. Two-fifths of the burden are due to modifiable risk factors, and a quarter of years lived with disability are attributable to occupational ergonomic factors.
Elsevier,
eClinicalMedicine, Volume 60, June 2023
This Article supports Sustainable Development Goal 3 by estimating the proportion of dementia attributable to hypertension, finding an overall global population attributable fraction of 15.8%. Results were also broken down by region and age. The authors note that the estimates from this study could help to inform public health policy at global and national levels.
Elsevier,
eBioMedicine, Volume 92, June 2023
This Article supports Sustainable Development Goal 3 by highlighting differential effects of sleep disturbances on resting-state neural activity in patients on the Alzheimer's disease spectrum relative to healthy adults, suggesting a key role of sleep disturbances in the neurophysiological changes seen in Alzheimer's disease, with implications for basic research and clinical intervention.
Elsevier,
eBioMedicine, Volume 92, June 2023
This Article supports Sustainable Development Goal 3 by describing a cohort characterization model for Alzheimer’s Disease built on medications and diagnoses data that are widely available in a structured format in electronic health records (EHRs), showing that standard machine learning applied to sequences of EHR data can produce scalable computational characterization of Alzheimer’s disease cohorts.
Elsevier,
The Lancet Regional Health - Europe, Volume 29, June 2023
This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
Elsevier,
The Lancet Global Health, Volume 11, June 2023
This Comment article supports SDG 3 and 16 by highlighting how complex humanitarian settings have become fertile environments for spreading misinformation, disinformation, and malinformation, and how the 2021 release of the Oxford Statement on International Law Protection in Cyberspace, which touches on sovereignty, incitement, human rights, criminal law, general rules of international humanitarian law, and international criminal law, is an important first step to address this type of disinformation.
Elsevier,
The Lancet Regional Health - Americas, Volume 22, June 2023, 100527
This News item supports SDG 3 by describing the work of the PAHO Commission on Mental Health and COVID-19, which was created in order to improve mental health care in the Latin America and Caribbean region in light of the mental health crisis resulting from the pandemic. The article describes the 10 recommendations set forth by the Commission, and the opportunities and implications of these recommendations.
